Fundraising Fox
Climb Bio
1 known investors
Find your way into Climb Bio
Each arrow is one introduction. Sign up to fill in the first one.
48 people can intro you to Ashley
Ask Rahul Ballal to introduce you to Ashley Jones
You →Rahul · together at Imara, Inc →Ashley
Sign up to find every way you can get introduced to Climb Bio
- Your email: who you already know at Climb Bio, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Climb Bio team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Climb Bio develops monoclonal antibody therapies for immune-mediated diseases, advancing clinical-stage candidates such as budoprutug for conditions including immune thrombocytopenia. Its investigational therapies target patients with limited treatment options.
Founders & leadership
AB
Aoife Brennan, MB, ChBPresident and Chief Executive Officer
PW
Perrin Wilson, PhDChief Business Officer
SA
Susan Altschuller, PhD, MBAChief Financial Officer
EC
Edgar Charles, MDChief Medical Officer
AJ
Ashley JonesSenior Vice President, People & Workforce StrategySenior Vice President of People & Workforce Strategy at Climb Bio, a clinical-stage biotech company developing monoclonal antibody therapies for immune-mediated diseases.
AV
Adam Villa, MBA, MSSenior Vice President, Technical Operations
CA
Chandra Adams, JDSenior Vice President, General Counsel
Investors · 1
Frequently asked questions
- What does Climb Bio do?
- Climb Bio develops monoclonal antibody therapies for immune-mediated diseases, advancing clinical-stage candidates such as budoprutug for conditions including immune thrombocytopenia. Its investigational therapies target patients with limited treatment options.
- Who are Climb Bio's investors?
- Climb Bio's investors include LifeArc Ventures.